2010National Medical Frontiers of ChinaRequires access

Changes of PC and AT-III in the patients with II diabetic nephropathy

Tong Feng-zh

Open publisher page 0 citations

Abstract

Objective To investigate the changes of serum Protein C (PC) and Antithrombin Ⅲ (AT-Ⅲ) in the early or late stage of the patients with diabetic nephropathy (DN) and explore the effect of PC and AT-Ⅲ in etiopathology and progression of DN. Methods The serum samples were collected from 125 Ⅱ diabetes mellitus (DM) patients and 38 controls, and the DM group was divided into non-albuminuria group (UAE30mg/24h, 45 samples) and albuminuria group (UAE30mmg/24h, 80 samples). Then, the level of PC and the activity of AT-Ⅲ were detected, respectively. Results Compared with controls (102.3±17.3%), the level of PC in both non-albuminuria group and albuminuria group significantly increased (non-albuminuria group: 124.1±10.7%, p 0.05; albuminuria group: 171.5±36.5%, p 0.05). In addition, the level of PC in the albuminuria group was significantly higher than that in the non-albuminuria group (p0.05). Compared with controls (95.4±6.5%), the activityl of AT-Ⅲ in both non-albuminuria group and albuminuria group significantly decreased (non-albuminuria group:79.4±29.4%, p 0.05); albuminuria group: 40.6± 13.2%(p 0.05). In addition, the acticvity of AT-Ⅲ in the albuminuria group was significantly lower than that in the non-albuminuria group (p 0.05). Conclusions It is obvious that DM patients have coagulation disorder and the degree of the disorder relates with the development of DM. PC and AT-Ⅲ can be used in monitoring the progression of DN, especially in the early stage.

About this research paper

What this paper is about

Objective To investigate the changes of serum Protein C (PC) and Antithrombin Ⅲ (AT-Ⅲ) in the early or late stage of the patients with diabetic nephropathy (DN) and explore the effect of PC and AT-Ⅲ in etiopathology and progression of DN. Methods The serum samples were collected from 125 Ⅱ diabetes mellitus (DM) patients and 38 controls, and the DM group was divided into non-albuminuria group (UAE30mg/24h, 45 samples) and albuminuria group (UAE30mmg/24h, 80 samples). Then, the level of PC and the activity of AT-Ⅲ were detected, respectively. Results Compared with controls (102.3±17.3%), the level of PC in both non-albuminuria group and albuminuria group significantly increased (non-albuminuria group: 124.1±10.7%, p 0.05; albuminuria group: 171.5±36.5%, p 0.05). In addition, the level of PC in the albuminuria group was significantly higher than that in the non-albuminuria group (p0.05). Compared with controls (95.4±6.5%), the activityl of AT-Ⅲ in both non-albuminuria group and albuminuria group significantly decreased (non-albuminuria group:79.4±29.4%, p 0.05); albuminuria group: 40.6± 13.2%(p 0.05). In addition, the acticvity of AT-Ⅲ in the albuminuria group was significantly lower than that in the non-albuminuria group (p 0.05). Conclusions It is obvious that DM patients have coagulation disorder and the degree of the disorder relates with the development of DM. PC and AT-Ⅲ can be used in monitoring the progression of DN, especially in the early stage.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To investigate the changes of serum Protein C (PC) and Antithrombin Ⅲ (AT-Ⅲ) in the early or late stage of the patients with diabetic nephropathy (DN) and explore the effect of PC and AT-Ⅲ in etiopathology and progression of DN. Methods The serum samples were collected from 125 Ⅱ diabetes mellitus (DM) patients and 38 controls, and the DM group was divided into non-albuminuria group (UAE30mg/24h, 45 samples) and albuminuria group (UAE30mmg/24h, 80 samples). Then, the level of PC and the activity of AT-Ⅲ were detected, respectively. Results Compared with controls (102.3±17.3%), the level of PC in both non-albuminuria group and albuminuria group significantly increased (non-albuminuria group: 124.1±10.7%, p 0.05; albuminuria group: 171.5±36.5%, p 0.05). In addition, the level of PC in the albuminuria group was significantly higher than that in the non-albuminuria group (p0.05). Compared with controls (95.4±6.5%), the activityl of AT-Ⅲ in both non-albuminuria group and albuminuria group significantly decreased (non-albuminuria group:79.4±29.4%, p 0.05); albuminuria group: 40.6± 13.2%(p 0.05). In addition, the acticvity of AT-Ⅲ in the albuminuria group was significantly lower than that in the non-albuminuria group (p 0.05). Conclusions It is obvious that DM patients have coagulation disorder and the degree of the disorder relates with the development of DM. PC and AT-Ⅲ can be used in monitoring the progression of DN, especially in the early stage.

Key concepts: Albuminuria, Medicine, Diabetic nephropathy, Diabetes mellitus, Internal medicine, Urology, Endocrinology, Nephropathy

Related papers

Back to paper searchBrowse research topicsOriginal source
Changes of PC and AT-III in the patients with II diabetic nephropathy — Research Paper | ScholarLens